Simpson, Rachel E.Yip-Schneider, MicheleFlick, Katelyn F.Soufi, MazharCeppa, Eugene P.Al-Haddad, Mohammad A.Easler, Jeffrey J.Sherman, StuartDewitt, John M.Schmidt, C. Max2021-09-242021-09-242020Simpson, R. E., Yip-Schneider, M., Flick, K. F., Soufi, M., Ceppa, E. P., Al-Haddad, M. A., Easler, J. J., Sherman, S., Dewitt, J. M., & Schmidt, C. M. (2020). Secretin-induced Duodenal Aspirate of Pancreatic Juice (SIDA): Utility of Commercial Genetic Analysis. Anticancer Research, 40(8), 4215–4221. https://doi.org/10.21873/anticanres.14422https://hdl.handle.net/1805/26651Background: Secretin-induced duodenal aspiration (SIDA) of pancreatic duct fluid has been proposed for pancreatic neoplasm screening in very high-risk patients. We sought to determine the clinical yield and safety of commercially-analyzed SIDA samples in patients at moderately elevated risk. Patients and Methods: A prospectively maintained institutional database of pancreatic fluid DNA profiles was retrospectively reviewed. Results: Fifty-seven patients underwent SIDA testing, most commonly for intraductal papillary mucinous neoplasms (n=43) and not otherwise specified solitary cysts (n=9). SIDA mutation yield was low compared to 37 concomitant endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) samples of pancreatic fluid: KRAS (2.5% vs. 40.0%), GNAS (2.6% vs. 11.1%) and allelic loss of heterozygosity (3.1% vs. 0%). Patients undergoing SIDA alone experienced no complications while 3 patients with concomitant EUS-FNA had post-procedural pancreatitis. Conclusion: The genetic yield of commercially-analyzed SIDA samples was relatively low in a moderately elevated risk cohort. SIDA testing may have a better safety profile than EUS-FNA.enPublisher Policypancreatic juicepancreatic neoplasmspancreatic cystArticle